Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Intermittent Rifampicin on Raltegravir (RIFRAL)

This study has been completed.
Sponsor:
Collaborator:
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Information provided by (Responsible Party):
Helen Reynolds, University of Liverpool
ClinicalTrials.gov Identifier:
NCT01424826
First received: August 24, 2011
Last updated: October 30, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)